This is a routine, tax-motivated sale from restricted stock vesting with no trading implications. Monitor for any larger insider dispositions or changes in senior leadership selling patterns, but this filing alone does not warrant a trade action.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $255.17entry
- T+1 · 5mo ago −0.69%α −2.46% · $253.40
- T+5 · 5mo ago −1.83%α −2.50% · $250.50
- T+20 · 4mo ago −8.37%α −10.15% · $233.80
- T+60 · 2mo ago −18.56%α −21.82% · $207.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Roger Jeffs filed a Form 144 to sell 286 shares of Axsome Therapeutics common stock, valued at approximately $70,407. The shares originated from a restricted stock lapse on June 6, 2026, and the sale appears to be a routine tax-withholding transaction. The dollar amount is negligible relative to the company's $12.7B market cap, making this filing inconsequential for traders.
Key Facts
- Director Roger Jeffs filed Form 144 to sell 286 shares of common stock.
- Estimated sale value of $70,407 based on June 10, 2026 trade.
- Shares originated from a restricted stock lapse (equity compensation) on June 6, 2026.
- Sale constitutes a trivial fraction of the company's $12.7B market capitalization.
- No indication of a Rule 10b5-1 trading plan (filing marked as 'LIVE'), but size and context suggest routine tax-motivated sale.
Financial Impact
Sale of 286 shares for ~$70,407, representing ~0.0006% of AXSM's market cap.
Risk Factors
- None material, extremely small relative to market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001921094-26-000636 |
| Document: 0001921094-26-000636-index.html | 0001921094-26-000636 |
| Document: 0001921094-26-000636.txt | 0001921094-26-000636 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers